Earlier, T2 Biosystems announced plans for the T2Lyme Panel commercial launch and provided recent business updates. The company stated that it continues to expect full year 2024 total sepsis and related product revenue of $10.0M-$11.0M, representing growth of 49%-64%, compared to $6.7M in 2023. “The company’s 2024 revenue guidance consists entirely of sepsis and related product revenue and does not include potential sales of the T2Lyme Panel or the T2Biothreat Panel,” T2 Biosystems said.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on TTOO:
- T2 Biosystems Unveils T2Lyme Launch Plans and Provides Additional Business Updates
- T2 Biosystems to Host Investor Call on March 20, 2024 to Unveil its T2Lyme Launch Plans and Provide Additional Business Updates
- T2 Biosystems Revolutionizes Infection Detection Efficiency
- T2 Biosystems announces new publication on T2Resistance Panel
- T2 Biosystems receives extension to comply with Nasdaq listing requirement
